Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
McKesson
Merck
Express Scripts
AstraZeneca

Last Updated: September 24, 2022

Patent: 5,385,839


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 5,385,839
Title: Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter regulatory DNA sequence
Abstract:The cloning of a eucaryotic promoter-regulatory region that functions preferentially in human cells is disclosed. The invention is exemplified by the cloning of a section of the human cytomegalovirus genome comprising a DNA sequence with regulatory and promoter signals and an initiation site for RNA synthesis. The fragment, termed the human cytomegalovirus (HCMV) promoter-regulatory sequence, was obtained from purified HCMV DNA.
Inventor(s): Stinski; Mark F. (Iowa City, IA)
Assignee: University of Iowa Research Foundation (Iowa City, IA)
Application Number:07/900,056
Patent Claims:see list of patent claims

Details for Patent 5,385,839

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. TYSABRI natalizumab Injection 125104 11/23/2004 See Plans and Pricing 2005-01-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Mallinckrodt
Express Scripts
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.